Last updated on May 2020

Safety Efficacy and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Brief description of study

This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene alterations and also to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BOS172738.

Clinical Study Identifier: NCT03780517

Find a site near you

Start Over

Prince of Wales Hospital

Hong Kong, Hong Kong
  Connect »